All lobbying filings
S-3 Group
S-3 Group filed a Q3 report for Novo Nordisk, Inc. on October 16, 2026, reporting $60,000 in lobbying income.
Lobbying for Novo Nordisk, Inc. · Pharmaceutical company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 16, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
7
-
MICHAELEEN EARLE CROWELLPreviously held: Leg Director, Rep. Denise Majette; Leg Director, Rep. John Lewis; Chief of Staff, US Sen. Bernie Sanders
-
MALLOY MCDANIELPreviously held: Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
-
MARTIN REISERPreviously held: Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget Committee
-
CHRISTOPHER BUKIPreviously held: Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley
-
KEVIN CASEYPreviously held: Senior Pol Dir, Dem Caucus; Counselor, Leg. Dir, Leg. Asst, Rep. Joseph Crowley; Staff Asst, Leg. Correspondent, Rep. Bob Weygand
-
OLIVIA KURTZPreviously held: Chief of Staff, Leg Director, Dep Leg Director, Sr Leg Asst, US Sen Susan Collins; Dep Staff Dir, Sen Special Comm on Aging; Leg Director, Sr Leg Asst, Leg Asst, Exec Asst, Rep Mike Castle
-
CHRIS ARNESON New on this filingPreviously held: Economic Policy Director, Chief Budget and Economic Advisor, Senior Tax Policy Advisor, Tax Policy Advisor, Research Associate, Research Assistant, Associate Investigator, Senate Finance Committee
Government bodies contacted
2
Lobbying activity
3
Issues related to compounding and counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to tariffs and importation of counterfeit drugs.